Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

November 16, 2023

Study Completion Date

January 18, 2024

Conditions
Lupus ErythematosusLupus Nephritis
Interventions
DRUG

Itolizumab [Bmab 600]

EQ001

Trial Locations (25)

10032

Columbia University Medical Center, Div of Nephrology, New York

10461

Albert Einstein College of Medicine, Montefiore Medical Center, The Bronx

11021

Northwell Health / Division of Rheumatology, Great Neck

18017

Northeast Clinical Research Center, LLC, Bethlehem

30046

Georgia Nephrology, Lawrenceville

32610

University of Florida, Division of Rheumatology, Gainesville

32810

Omega Research Maitland, LLC, Orlando

33136

SouthCoast Research Center Inc, Miami

33165

Hope Clinical Trials, Miami

33309

Centre for Rheumatology, Immunology and Arthritis, Fort Lauderdale

33603

Clinical Research of West Florida - Tampa, Tampa

33606

University of South Florida, Tampa

34748

Clinical Site Partners Leesburg, LLC, Leesburg

75230

Dallas Renal Group, Dallas

77054

Prolato Clinical Research Center (PCRC), Houston

85351

AKDHC Medical Research Services, LLC, Sun City

91910

California Institute of Renal Research, Chula Vista

92037

University of California San Diego Perlman Ambulatory Clinic, La Jolla

33765-2616

Clinical Research of West Florida - Clearwater, Clearwater

Unknown

Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh

Medanta - The Medicity Hospital, Gurugramam

MAX Super Specialty Hospital, New Delhi

Jawaharlal Nehru Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry

92-213

SP ZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi, Klinika Nefrologii, Hipertensjologii, Lodz

04-749

Miedzyleski Szpital Specjalistyczny w Warszawie, Oddzial Nefrologiczny i Stacja Dializ, Warsaw

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Biocon Limited

INDUSTRY

lead

Equillium

INDUSTRY

NCT04128579 - Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis | Biotech Hunter | Biotech Hunter